01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
DexCom (DXCM) furnished an 8-K on January 12, 2026 to accompany CEO Jake Leach's remarks at the J.P.
Morgan Healthcare Conference, disclosing preliminary, unaudited results for Q4 and full-year 2025 along with initial 2026 guidance. Q4 2025 total revenue is approximately $1.260 billiona, up 13% year over year, with U.S. revenue of about $892 million (+11%) and international revenue of about $368 million (+18%). Full-year 2025 preliminary revenue is approximately $4.662 billion, up 16% from 2024, and management said revenue exceeded the high end of its guidance.
The company reiterated 2025 non-GAAP gross margin guidance of roughly 61% and non-GAAP operating margin guidance of 20-21%. For 2026, Dexcom guided to total revenue of $5.16b-$5.25 billion, implying growth of roughly 11-13%, driven by sensor volume growth from rising CGM awareness, the continued rollout of Stelo, and international expansion. Non-GAAP gross margin is expected to expand to approximately 63-64% and non-GAAP operating margin to approximately 22-23%, indicating meaningful profitability improvement.
The 2026 outlook is a notable step-up in margin expectations, though the figures remain preliminary and subject to audit. The filing also attaches a January 7, 2026 press release announcing that Jake Leach assumed the President and CEO role on January 1, succeeding Kevin Sayer, along with plans for a reimagined Stelo app and the pharmacy launch of the G7 15 Day system. Audited full-year results are scheduled for release on February 12, 2026, and investors should treat these preliminary figures as subject to finalization in the 10-K.
02—Key points
Key Highlights
- Q4 2025 preliminary revenue of ~$1.260B, up 13% YoY; U.S. ~$892M (+11%) and International ~$368M (+18%)
- FY2025 preliminary revenue of ~$4.662B, up 16% YoY, exceeding the high end of company guidance
- 2026 revenue guidance of $5.16-$5.25B, implying approximately 11-13% growth
- 2026 non-GAAP gross profit margin guided to ~63-64%, up from ~61% in 2025
- 2026 non-GAAP operating margin guided to ~22-23%, up from 20-21% in 2025
- Jake Leach formally became President and CEO on January 1, 2026, succeeding Kevin Sayer
- Audited Q4 and FY2025 results to be released February 12, 2026, with figures subject to change until then
03—Questions
Frequently Asked Questions
Are the 2025 results final?
No. The Q4 and fiscal 2025 figures are preliminary and unaudited, and remain subject to finalization in the Form 10-K. Dexcom plans to report audited results on February 12, 2026.
What is driving the expected 2026 growth?
Management cites sensor volume growth from increasing CGM awareness among people with diabetes, the continued rollout of the Stelo consumer product, further international expansion, and overall market dynamics.
Why are the 2026 margin targets significant?
The guided non-GAAP gross margin of 63-64% and operating margin of 22-23% both exceed 2025 levels, suggesting expected operating leverage and improved profitability as revenue scales.
Did the leadership change affect the company's outlook?
Leach, who previously served as COO, took over as CEO on January 1, 2026, and the company presented its 2026 outlook and milestones under his leadership at the J.P. Morgan conference. The filing does not indicate any change in strategic direction.
What risks should investors consider?
Guidance is forward-looking and subject to the risks described in Dexcom's Risk Factors and MD&A sections of its 10-K and 10-Q filings. Investors should also watch for any changes when audited results are published, as well as the pace of pharmacy distribution for the G7 15 Day system, where the company noted some sensors may not last the full 15 days.
04—Continue